Allergy & Immunology
Cohort study: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S. 11 excess venous thromboembolic events per 100 000 vaccinations; 2.5 excess cerebral venous thrombosis per 100 000 vaccinations.
7 May, 2021 | 08:33h | UTCEditorial: Thromboembolism and the Oxford-AstraZeneca vaccine – The BMJ
Commentaries: Thrombosis and bleeding after the Oxford-AstraZeneca covid-19 vaccination – The BMJ Opinion AND Putting risks into context: covid-19 vaccines and blood clots – The BMJ Opinion AND Expert reaction to study from Denmark and Norway looking at rare blood clots after the Oxford-AstraZeneca vaccine – Science Media Centre
Commentary on Twitter
NEW research sheds more light on rate of rare blood clots after Oxford-AstraZeneca vaccine
Rate of adverse events low; benefits of the vaccine still outweigh risks in most situations, say researchershttps://t.co/LslgvzWlWi @Pottegard
— The BMJ (@bmj_latest) May 6, 2021
The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity
7 May, 2021 | 08:30h | UTC
Commentary on Twitter
We forget that covid-19 is a new disease, never having been seen until late 2019, w/ different features than any prior illness. A truly outstanding review today on its pathophysiology https://t.co/8gx2w8r1xf @LancetRespirMed @osuchm and colleagues pic.twitter.com/WGIfI2nb9B
— Eric Topol (@EricTopol) May 6, 2021
Observational study in Qatar: Pfizer–BioNTech Covid vaccine is 89.5% effective against B.1.1.7 variant and 75.0% effective against B.1.351 variant. Vaccine effectiveness against severe, critical, or fatal disease with any SARS-CoV-2 variant was very high, at 97.4%.
6 May, 2021 | 09:06h | UTC
Commentary on Twitter
📍GET BOTH DOSES! Great variants & #COVID19 vaccine news—Pfizer/BioNTech vaccine had great efficacy of 89.5% vs #B117 🇬🇧 variant & 75% vs #B1351 🇿🇦 variant for infection—but only with 2 doses. The 1 dose efficacy was just ~29% vs #B117 & ~17% vs #B1351. 🧵https://t.co/SprUfggnmh pic.twitter.com/VDWHiLsQLL
— Eric Feigl-Ding (@DrEricDing) May 6, 2021
Organ transplant recipients remain vulnerable to Covid-19 even after second vaccine dose.
6 May, 2021 | 09:03h | UTCOriginal Study: Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients – JAMA
Cohort study shows inadequate antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients.
6 May, 2021 | 09:01h | UTC
Commentary on Twitter
The studies of mRNA vax in people with transplants are getting bigger: still the same message. Some protection, but not enough. This time, 308 people with kidney transplants in Israel, BNT-Pfizer vaccine https://t.co/Otvt8F11my
— Hilda Bastian, PhD (@hildabast) May 6, 2021
[Preprint] SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity
5 May, 2021 | 08:40h | UTCCommentary: SARS-CoV-2 antibodies are detectable up to a year after infection, finds study – News Medical
Commentary on Twitter
Ahhh… A year has passed since people with Covid-19 were enrolled in a longitudinal study at 7 US military hospitals. Only a small number checked 12 months later, but signs of immunity still. Immune responses lasting even after milder infection https://t.co/VWsqG8gulT Preprint
— Hilda Bastian, PhD (@hildabast) May 2, 2021
Prior SARS-CoV-2 infection boosts response to variants after first vaccine dose
4 May, 2021 | 08:51h | UTCOriginal study: Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose – Science
Commentary on Twitter (thread – click for more)
Just published @ScienceMagazine
"After one dose, individuals with *prior infection* showed enhanced T cell immunity, antibody secreting memory B cell response to spike and neutralizing antibodies effective against B.1.1.7 and B.1.351." 👍https://t.co/7cCVM6iqdP pic.twitter.com/GiC43bjwZZ— Eric Topol (@EricTopol) April 30, 2021
Study: Most patients who develop a non-IgE-mediated hypersensitivity reaction to nafcillin can be safely treated with cefazolin
4 May, 2021 | 08:36h | UTC
Commentary on Twitter
New case series found 90% tolerated switching to cefazolin out of 80 patients who experienced non-IgE hypersensitivity reactions to nafcillin.https://t.co/YbFeWS4n4k
Our previous metas-analysis https://t.co/sJBjrx4a3r found higher odds of these reactions with nafcillin. pic.twitter.com/SIWcSuPcct— Antibiotic Tweets 🦠 (@khalideljaaly) April 28, 2021
Case series of 12 patients with cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination – all women younger than 60 years, with symptoms from 6 to 15 days after vaccination
3 May, 2021 | 05:43h | UTCSee also: Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021 – Centers for Disease Control and Prevention AND Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021 – Centers for Disease Control and Prevention
Review: Systemic and organ-specific immune-related manifestations of COVID-19 – over 70 different systemic and organ-specific immune-related disorders have been reported
28 Apr, 2021 | 08:42h | UTCSystemic and organ-specific immune-related manifestations of COVID-19 – Nature Reviews Rheumatology
Long Covid: Largest post-acute COVID-19 study to date examined the health outcomes in more than 73,000 people who’d had COVID-19 and were not hospitalized
23 Apr, 2021 | 08:48h | UTCHigh-dimensional characterization of post-acute sequalae of COVID-19 – Nature
Commentary on Twitter (thread – click for more)
Happy to share the latest paper from our team in @nature
A comprehensive characterization of post acute sequelae of COVID-19#longcovid #PASChttps://t.co/AGLnYCamWe@VAResearch @vahsrd @WUSTL @WUSTLpubhealth @WUSTLmed @WUSTLnews @VREFSTL @Biostayan @BCBowe
— Ziyad Al-Aly, MD (@zalaly) April 22, 2021
RCT: Single-Dose Johnson & Johnson Vaccine has 85% efficacy against severe/critical Covid-19 and maintains efficacy against variant B.1.351
22 Apr, 2021 | 08:50h | UTC
Guideline: Diagnosis and Evaluation of Hypersensitivity Pneumonitis
22 Apr, 2021 | 08:21h | UTCSee also: Executive Summary
Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease
22 Apr, 2021 | 08:40h | UTC
Commentaries on Twitter
Early data from @RCHMelbourne show that, at 3-6 month follow-up, all 151 children with mild and asymptomatic #COVID19 had returned to their baseline health status and post-acute COVID-19 symptoms had resolved.
Letter from @Shidan_Tosif & colleagues: https://t.co/XXa0EPIgPY
— The Lancet Child & Adolescent Health (@LancetChildAdol) April 20, 2021
Given such little available data, this study from Australia on post-acute COVID-19 symptoms in children is very important
Findings are extremely reassuring
Post-acute symptoms were rare, and mild (cough 4%, fatigue 2%, cough and fatigue 1%)
Great news!https://t.co/TEJyES3Crx
— Alasdair Munro (@apsmunro) April 21, 2021
Great to see research looking at whether long Covid is a problem in children.
From this Melbourne cohort, enduring cough and fatigue are uncommon.
It hasn’t been clear to me whether borders will reopen before children are vaccinated so this is VIP https://t.co/iLXqwXJmOt
— Jin Russell (@DrJinRussell) April 21, 2021
Truly encouraging data on post-acute #COVID19 in children. Single-center in Australia. n=151.
8% post-acute symptoms – all symptomatic COVID-19.
Mild symptoms: cough 4%, fatigue 2%, both 1%. Duration: cough 3-8w; post-viral fatigue 6-8w. All solved in follow-up time 3-6 months. https://t.co/vKrEFZlw3C— Dr Pablo Guisado Vasco MD, PhD (@PabloGVasco) April 21, 2021
ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia
21 Apr, 2021 | 07:11h | UTCSee also: Diagnostic Flow Chart
Commentary on Twitter
The ISTH has released interim guidance on vaccine-induced immune thrombotic thrombocytopenia (#VITT) to inform the management of suspected thrombosis in subjects who have recently received the AstraZeneca or Johnson & Johnson vaccine. https://t.co/qqtQtpywaf pic.twitter.com/wNmjNNDs4z
— ISTH (@isth) April 20, 2021
COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
21 Apr, 2021 | 07:07h | UTCCommentary: Johnson & Johnson vaccine: EU regulator says blood clot very rare side effect – BBC
Commentary on Twitter
EMA has concluded there is a possible link between TTS (thrombosis & thrombocytopenia syndrome) & the J&J vaccine, & they will be adding it as a rare side effect to the product information: the same as for AZ, but so far reported at a much lower rate…1/n https://t.co/aonOEObeHR
— Hilda Bastian, PhD (@hildabast) April 20, 2021
[News release – not published yet] Sputnik V demonstrates 97.6% efficacy according to the analysis of data of 3.8 million vaccinated persons in Russia
20 Apr, 2021 | 06:08h | UTC
Commentary on Twitter
Press release from Russia on Sputnik V claiming effectiveness is 97.6% based on a comparison of the infection rate of people fully vaxed & those with confirmed Covid-19; says a publication in the works, but no mention of safety data…1/n https://t.co/7V5cbUxTSV
— Hilda Bastian, PhD (@hildabast) April 19, 2021
Pfizer CEO says third Covid vaccine dose likely needed within 12 months
20 Apr, 2021 | 06:02h | UTCPfizer CEO says third Covid vaccine dose likely needed within 12 months – CNBC
Commentary: Fully Vaccinated? Get Ready For Your Third Dose – Forbes
China’s Sinovac COVID-19 vaccine 67% effective in preventing symptomatic infection, 85% effective in preventing hospitalizations and 80% effective in preventing deaths – Chile govt report
18 Apr, 2021 | 21:45h | UTC
Commentary on Twitter (thread – click for more)
Sinovac's CoronaVac in Chile: for Feb-Mar, during major outbreak. Data from National Health Fund, comparisons adjusted for age, gender, region, income, nationality. Fully vaccinated after 14 days was effective; 1 dose wasn't …1/nhttps://t.co/lNqGqTy7mv (TY for all the alerts!) pic.twitter.com/q1Fk2D3aek
— Hilda Bastian, PhD (@hildabast) April 16, 2021
Study shows antihistamines may impair response to exercise training
16 Apr, 2021 | 06:06h | UTCCommentary: Histamine-suppressing drugs found to reduce benefits of exercise – MedicalXpress
Commentary on Twitter (thread – click for more)
Extremely excited to finally share our newest paper: Histamine H1 and H2 receptors are essential transducers of the integrative exercise training response in humans. Published today in @ScienceAdvances. A thread: (1/12)https://t.co/R4FNiKWyG9 pic.twitter.com/U2HFHOY9eA
— Thibaux Van der Stede (@ThibauxV) April 14, 2021
[Preprint] Risk of rare blood clotting much higher for COVID-19 than for vaccines
16 Apr, 2021 | 06:37h | UTCNews release: Risk of rare blood clotting higher for COVID-19 than for vaccines – University of Oxford
Original study (preprint): Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases and a comparison with 489,871 people receiving a COVID-19 mRNA vaccine
Commentaries: Brain clots ‘more likely’ with Covid infection than vaccine – BBC AND Risk for Cerebral Venous Thrombosis Elevated After COVID-19 Diagnosis – NEJM Journal Watch AND Study: COVID much more likely than vaccines to cause blood clots – CIDRAP
Commentary on Twitter
There is an interesting new preprint out that will probably generate a lot of coverage at least in the UK. Essentially it argues that the risk of CVST is much higher from #covid19 than from vaccines.
Quick thread on this:https://t.co/0MdDU2z9bp— Kai Kupferschmidt (@kakape) April 15, 2021
Case Report: Thrombotic Thrombocytopenia after Johnson & Johnson Vaccine
15 Apr, 2021 | 07:02h | UTCThrombotic Thrombocytopenia after Ad26.COV2.S Vaccination – New England Journal of Medicine
Related: U.S. regulators pause Johnson & Johnson vaccine rollout over rare (1 in a million) cases of blood clots AND 4 Things to Know About the J&J Covid Vaccine Pause – Kaiser Health News AND Why Johnson & Johnson shots were paused — and why that’s so confusing – Vox AND Is it the adenovirus vaccine technology, used by AstraZeneca and Johnson & Johnson, causing blood clots? There’s no evidence yet – The Conversation
Diagnosis and management of leukocytoclastic vasculitis
14 Apr, 2021 | 01:26h | UTCDiagnosis and management of leukocytoclastic vasculitis – Internal and Emergency Medicine
RCT: Inhaled budesonide shortens recovery time in non-hospitalized patients with COVID-19
13 Apr, 2021 | 05:30h | UTCOriginal study (preprint): Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial – medRxiv
Commentary: Covid: Asthma drug ‘speeds up recovery at home’ – BBC
Related study: Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19 (study and commentaries)
[Preprint] Pfizer vaccine less effective for SARS-CoV-2 variant B.1.351
12 Apr, 2021 | 01:26h | UTCCommentaries: South African variant may evade protection from Pfizer vaccine, Israeli study says – Reuters AND Israeli data shows South African variant able to ‘break through’ Pfizer vaccine – The Times of Israel
Related: Another study indicates SARS-CoV-2 variant B.1.351, but not variant B.1.1.7, has partial resistance to neutralizing antibodies generated by natural infection or mRNA vaccination AND SARS-CoV-2 variants B.1.351 and P.1 can escape from therapeutic antibodies and evade antibodies induced by infection or mRNA vaccination AND B.1.351 strain of SARS-CoV-2 neutralization titer reduced 8- to 9-fold for Pfizer and AstraZeneca vaccinees. Convalescent plasma and therapeutic antibodies were less effective against this variant as well.